O	0	9	Autocrine	Autocrine	NN	B-NP
O	10	21	angiotensin	angiotensin	NN	I-NP
O	22	28	system	system	NN	I-NP
O	29	39	regulation	regulation	NN	I-NP
O	40	42	of	of	IN	B-PP
O	43	49	bovine	bovine	JJ	B-NP
B-Cell	50	56	aortic	aortic	JJ	I-NP
I-Cell	57	68	endothelial	endothelial	JJ	I-NP
I-Cell	69	73	cell	cell	NN	I-NP
O	74	83	migration	migration	NN	I-NP
O	84	87	and	and	CC	O
O	88	99	plasminogen	plasminogen	NN	B-NP
O	100	109	activator	activator	NN	I-NP
O	110	118	involves	involve	VBZ	B-VP
O	119	129	modulation	modulation	NN	B-NP
O	130	132	of	of	IN	B-PP
O	133	138	proto	proto	AFX	B-NP
O	138	139	-	-	HYPH	I-NP
O	139	147	oncogene	oncogene	NN	B-NP
O	148	153	pp60c	pp60c	NN	I-NP
O	153	154	-	-	HYPH	B-NP
O	154	157	src	src	NN	I-NP
O	158	168	expression	expression	NN	I-NP
O	168	169	.	.	.	O

O	170	175	Rapid	Rapid	JJ	B-NP
B-Cell	176	187	endothelial	endothelial	JJ	I-NP
I-Cell	188	192	cell	cell	NN	I-NP
O	193	202	migration	migration	NN	I-NP
O	203	206	and	and	CC	O
O	207	217	inhibition	inhibition	NN	B-NP
O	218	220	of	of	IN	B-PP
O	221	231	thrombosis	thrombosis	NN	B-NP
O	232	235	are	be	VBP	B-VP
O	236	244	critical	critical	JJ	B-ADJP
O	245	248	for	for	IN	B-PP
O	249	252	the	the	DT	B-NP
O	253	263	resolution	resolution	NN	I-NP
O	264	266	of	of	IN	B-PP
O	267	277	denudation	denudation	NN	B-NP
O	278	286	injuries	injury	NNS	I-NP
O	287	289	to	to	TO	B-PP
O	290	293	the	the	DT	B-NP
B-Multi-tissue_structure	294	300	vessel	vessel	NN	I-NP
I-Multi-tissue_structure	301	305	wall	wall	NN	I-NP
O	305	306	.	.	.	O

O	307	317	Inhibition	Inhibition	NN	B-NP
O	318	320	of	of	IN	B-PP
O	321	324	the	the	DT	B-NP
B-Cell	325	336	endothelial	endothelial	JJ	I-NP
I-Cell	337	341	cell	cell	NN	I-NP
O	342	351	autocrine	autocrine	NN	I-NP
O	352	363	angiotensin	angiotensin	NN	I-NP
O	364	370	system	system	NN	I-NP
O	370	371	,	,	,	O
O	372	376	with	with	IN	B-PP
O	377	383	either	either	CC	O
O	384	387	the	the	DT	B-NP
O	388	399	angiotensin	angiotensin	NN	I-NP
O	399	400	-	-	HYPH	O
O	400	410	converting	convert	VBG	B-VP
O	411	417	enzyme	enzyme	NN	B-NP
O	418	427	inhibitor	inhibitor	NN	I-NP
O	428	438	lisinopril	lisinopril	NN	I-NP
O	439	441	or	or	CC	O
O	442	445	the	the	DT	B-NP
O	446	457	angiotensin	angiotensin	NN	I-NP
O	458	460	II	II	CD	I-NP
O	461	469	receptor	receptor	NN	I-NP
O	470	480	antagonist	antagonist	NN	I-NP
O	481	485	sar1	sar1	NN	I-NP
O	485	486	,	,	,	O
O	487	491	ile8	ile8	NN	B-NP
O	491	492	-	-	HYPH	O
O	492	503	angiotensin	angiotensin	NN	B-NP
O	504	506	II	II	CD	I-NP
O	506	507	,	,	,	O
O	508	513	leads	lead	VBZ	B-VP
O	514	516	to	to	TO	B-PP
O	517	526	increased	increase	VBN	B-NP
B-Cell	527	538	endothelial	endothelial	JJ	I-NP
I-Cell	539	543	cell	cell	NN	I-NP
O	544	553	migration	migration	NN	I-NP
O	554	557	and	and	CC	I-NP
O	558	567	urokinase	urokinase	NN	I-NP
O	567	568	-	-	HYPH	B-NP
O	568	572	like	like	JJ	I-NP
O	573	584	plasminogen	plasminogen	NN	I-NP
O	585	594	activator	activator	NN	I-NP
O	595	596	(	(	(	O
O	596	597	u	u	NN	B-NP
O	597	598	-	-	HYPH	B-NP
O	598	600	PA	PA	NN	I-NP
O	600	601	)	)	)	O
O	602	610	activity	activity	NN	B-NP
O	611	612	(	(	(	O
O	612	616	Bell	Bell	NNP	B-NP
O	616	617	,	,	,	O
O	618	619	L	L	NNP	B-NP
O	619	620	.	.	NN	I-NP
O	620	621	,	,	,	O
O	622	625	and	and	CC	O
O	626	627	J	J	NNP	B-NP
O	627	628	.	.	.	I-NP
O	629	630	A	A	NNP	I-NP
O	630	631	.	.	.	I-NP
O	632	637	Madri	Madri	NNP	I-NP
O	637	638	.	.	.	I-NP
O	639	643	1990	1990	CD	I-NP
O	643	644	.	.	.	O
O	645	647	Am	Am	NNP	B-NP
O	647	648	.	.	.	I-NP
O	649	650	J	J	NNP	I-NP
O	650	651	.	.	.	I-NP
O	652	658	Pathol	Pathol	NNP	I-NP
O	658	659	.	.	.	I-NP
O	660	663	137	137	CD	I-NP
O	663	664	:	:	:	O
O	664	665	7	7	CD	B-NP
O	665	666	-	-	HYPH	I-NP
O	666	668	12	12	CD	I-NP
O	668	669	)	)	)	O
O	669	670	.	.	.	O

O	671	681	Inhibition	Inhibition	NN	B-NP
O	682	684	of	of	IN	B-PP
O	685	688	the	the	DT	B-NP
O	689	698	autocrine	autocrine	JJ	I-NP
O	699	710	angiotensin	angiotensin	NN	I-NP
O	711	717	system	system	NN	I-NP
O	718	722	with	with	IN	B-PP
O	723	726	the	the	DT	B-NP
O	727	737	converting	convert	VBG	I-NP
O	737	738	-	-	HYPH	I-NP
O	738	744	enzyme	enzyme	NN	I-NP
O	745	754	inhibitor	inhibitor	NN	I-NP
O	755	757	or	or	CC	O
O	758	761	the	the	DT	B-NP
O	762	770	receptor	receptor	NN	I-NP
O	771	781	antagonist	antagonist	NN	I-NP
O	782	786	also	also	RB	B-ADVP
O	787	792	leads	lead	VBZ	B-VP
O	793	795	to	to	TO	B-PP
O	796	805	increased	increase	VBN	B-NP
O	806	816	expression	expression	NN	I-NP
O	817	819	of	of	IN	B-PP
O	820	823	the	the	DT	B-NP
O	824	829	proto	proto	AFX	I-NP
O	829	830	-	-	HYPH	I-NP
O	830	838	oncogene	oncogene	NN	I-NP
O	839	840	c	c	NN	I-NP
O	840	841	-	-	HYPH	B-NP
O	841	844	src	src	NN	I-NP
O	844	845	:	:	:	O
O	846	851	pp60c	pp60c	NN	B-NP
O	851	852	-	-	HYPH	B-NP
O	852	855	src	src	NN	I-NP
O	856	860	mRNA	mRNA	NN	I-NP
O	861	870	increased	increase	VBD	B-VP
O	871	872	7	7	CD	B-NP
O	872	873	-	-	HYPH	I-NP
O	873	875	11	11	CD	I-NP
O	875	876	-	-	HYPH	B-VP
O	876	880	fold	fold	RB	B-ADVP
O	880	881	,	,	,	O
O	882	883	c	c	NN	B-NP
O	883	884	-	-	HYPH	I-NP
O	884	887	src	src	NN	I-NP
O	888	895	protein	protein	NN	I-NP
O	896	897	3	3	CD	I-NP
O	897	898	-	-	HYPH	B-VP
O	898	902	fold	fold	RB	B-ADVP
O	902	903	,	,	,	O
O	904	907	and	and	CC	O
O	908	909	c	c	NN	B-NP
O	909	910	-	-	HYPH	I-NP
O	910	913	src	src	NN	I-NP
O	914	920	kinase	kinase	NN	I-NP
O	921	929	activity	activity	NN	I-NP
O	930	931	2	2	CD	I-NP
O	931	932	-	-	HYPH	I-NP
O	932	933	3	3	CD	I-NP
O	933	934	-	-	HYPH	B-VP
O	934	938	fold	fold	RB	B-ADVP
O	938	939	.	.	.	O

B-Cell	940	951	Endothelial	Endothelial	JJ	B-NP
I-Cell	952	956	cell	cell	NN	I-NP
O	957	967	expression	expression	NN	I-NP
O	968	970	of	of	IN	B-PP
O	971	972	c	c	NN	B-NP
O	972	973	-	-	HYPH	B-NP
O	973	976	src	src	NN	I-NP
O	977	980	was	be	VBD	B-VP
O	981	995	constitutively	constitutively	RB	B-ADJP
O	996	1004	elevated	elevated	JJ	I-ADJP
O	1005	1010	after	after	IN	B-PP
O	1011	1017	stable	stable	JJ	B-NP
O	1018	1027	infection	infection	NN	I-NP
O	1028	1032	with	with	IN	B-PP
O	1033	1034	a	a	DT	B-NP
O	1035	1045	retroviral	retroviral	JJ	I-NP
O	1046	1052	vector	vector	NN	I-NP
O	1053	1063	containing	contain	VBG	B-VP
O	1064	1067	the	the	DT	B-NP
O	1068	1069	c	c	NN	I-NP
O	1069	1070	-	-	HYPH	B-NP
O	1070	1073	src	src	NN	I-NP
O	1074	1080	coding	coding	NN	I-NP
O	1081	1089	sequence	sequence	NN	I-NP
O	1089	1090	.	.	.	O

O	1091	1105	Constitutively	Constitutively	RB	B-NP
O	1106	1115	increased	increase	VBN	I-NP
O	1116	1117	c	c	NN	I-NP
O	1117	1118	-	-	HYPH	B-NP
O	1118	1121	src	src	NN	I-NP
O	1122	1128	kinase	kinase	NN	I-NP
O	1129	1137	activity	activity	NN	I-NP
O	1138	1151	reconstituted	reconstitute	VBD	B-VP
O	1152	1155	the	the	DT	B-NP
O	1156	1165	increases	increase	NNS	I-NP
O	1166	1168	in	in	IN	B-PP
O	1169	1178	migration	migration	NN	B-NP
O	1179	1182	and	and	CC	I-NP
O	1183	1184	u	u	NN	I-NP
O	1184	1185	-	-	HYPH	B-NP
O	1185	1187	PA	PA	NN	I-NP
O	1188	1196	observed	observe	VBN	B-VP
O	1197	1201	with	with	IN	B-PP
O	1202	1213	angiotensin	angiotensin	NN	B-NP
O	1214	1220	system	system	NN	I-NP
O	1221	1233	interruption	interruption	NN	I-NP
O	1233	1234	.	.	.	O

O	1235	1243	Antisera	Antiserum	NNS	B-NP
O	1244	1246	to	to	TO	B-PP
O	1247	1253	bovine	bovine	JJ	B-NP
O	1254	1255	u	u	NN	I-NP
O	1255	1256	-	-	HYPH	B-NP
O	1256	1258	PA	PA	NN	I-NP
O	1259	1266	blocked	block	VBD	B-VP
O	1267	1270	the	the	DT	B-NP
O	1271	1279	increase	increase	NN	I-NP
O	1280	1282	in	in	IN	B-PP
O	1283	1292	migration	migration	NN	B-NP
O	1293	1303	associated	associate	VBN	B-VP
O	1304	1308	with	with	IN	B-PP
O	1309	1318	increased	increase	VBN	B-NP
O	1319	1320	c	c	NN	I-NP
O	1320	1321	-	-	HYPH	O
O	1321	1324	src	src	NN	B-NP
O	1325	1335	expression	expression	NN	I-NP
O	1335	1336	.	.	.	O

O	1337	1342	These	These	DT	B-NP
O	1343	1347	data	datum	NNS	I-NP
O	1348	1355	suggest	suggest	VBP	B-VP
O	1356	1360	that	that	IN	B-SBAR
O	1361	1370	increases	increase	NNS	B-NP
O	1371	1373	in	in	IN	B-PP
B-Cell	1374	1385	endothelial	endothelial	JJ	B-NP
I-Cell	1386	1390	cell	cell	NN	I-NP
O	1391	1400	migration	migration	NN	I-NP
O	1401	1404	and	and	CC	I-NP
O	1405	1416	plasminogen	plasminogen	NN	I-NP
O	1417	1426	activator	activator	NN	I-NP
O	1427	1432	after	after	IN	B-PP
O	1433	1444	angiotensin	angiotensin	NN	B-NP
O	1445	1451	system	system	NN	I-NP
O	1452	1462	inhibition	inhibition	NN	I-NP
O	1463	1466	are	be	VBP	B-VP
O	1467	1469	at	at	IN	B-ADVP
O	1470	1475	least	least	JJS	I-ADVP
O	1476	1485	partially	partially	RB	B-NP
O	1486	1491	pp60c	pp60c	NN	I-NP
O	1491	1492	-	-	HYPH	B-NP
O	1492	1495	src	src	NN	I-NP
O	1496	1504	mediated	mediate	VBN	B-VP
O	1504	1505	.	.	.	O

O	1506	1514	Elevated	Elevate	VBN	B-NP
O	1515	1516	c	c	NN	I-NP
O	1516	1517	-	-	HYPH	O
O	1517	1520	src	src	NN	B-NP
O	1521	1531	expression	expression	NN	I-NP
O	1532	1536	with	with	IN	B-PP
O	1537	1548	angiotensin	angiotensin	NN	B-NP
O	1549	1555	system	system	NN	I-NP
O	1556	1566	inhibition	inhibition	NN	I-NP
O	1567	1570	may	may	MD	B-VP
O	1571	1574	act	act	VB	I-VP
O	1575	1577	to	to	TO	I-VP
O	1578	1585	enhance	enhance	VB	I-VP
B-Pathological_formation	1586	1593	intimal	intimal	JJ	B-NP
I-Pathological_formation	1594	1599	wound	wound	NN	I-NP
O	1600	1607	closure	closure	NN	I-NP
O	1608	1611	and	and	CC	O
O	1612	1614	to	to	TO	B-VP
O	1615	1621	reduce	reduce	VB	I-VP
B-Immaterial_anatomical_entity	1622	1629	luminal	luminal	JJ	B-NP
O	1630	1645	thrombogenicity	thrombogenicity	NN	I-NP
O	1646	1648	in	in	FW	B-ADVP
O	1649	1653	vivo	vivo	FW	I-ADVP
O	1653	1654	.	.	.	O

